{"mainPropery":{"diseaseId":7695,"diseaseName":"Succinic semialdehyde dehydrogenase deficiency","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7695/succinic-semialdehyde-dehydrogenase-deficiency","synonyms":["4-hydroxybutyric aciduria","Gamma-hydroxybutyricaciduria","SSADH deficiency","GABA metabolic defect"],"synonyms-with-source":[{"name":"4-hydroxybutyric aciduria"},{"name":"Gamma-hydroxybutyricaciduria"},{"name":"SSADH deficiency"},{"name":"GABA metabolic defect"}],"identifiers":[{"identifierType":"OMIM","identifierId":"271980"},{"identifierType":"ORPHANET","identifierId":"22"},{"identifierType":"UMLS","identifierId":"C0268631"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":14,"diseaseTypeName":"Metabolic disorders"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":138,"resourceName":"Metabolic Support UK","abbreviation":"","address1":"5 Hilliards Court","address2":"Sandpiper Way","address3":"Chester Business Park","address4":"","address5":"","city":"Chester","state":"","zip":"CH4 9QP","country":"United Kingdom","phone":"0845 241 2173","tty":"","tollFree":"0800 652 3181 ","fax":"","email":"https://www.metabolicsupportuk.org/contact-us","url":"https://www.metabolicsupportuk.org","freeText":""},{"resourceID":201,"resourceName":"American Association on Intellectual and Developmental Disabilities","abbreviation":"","address1":"501 3rd Street NW","address2":"Suite 200","address3":"","address4":"","address5":"","city":"Washington","state":"DC","zip":"20001","country":"United States","phone":"(202) 387-1968","tty":"","tollFree":"(800) 424-3688","fax":"(202) 387-2193","email":"","url":"http://www.aaidd.org","freeText":""},{"resourceID":413,"resourceName":"Epilepsy Foundation","abbreviation":"","address1":"8301 Professional Place East","address2":"Suite 230","address3":"","address4":"","address5":"","city":"Landover","state":"MD","zip":"20785","country":"United States","phone":"+1-301-459-3700 ","tty":"","tollFree":"800-332-1000 (24/7 Helpline)","fax":"+1-301-577-2684","email":"contactus@efa.org","url":"https://www.epilepsy.com/","freeText":"en Espa√±ol 1-866-748-8008"},{"resourceID":428,"resourceName":"Developmental Delay Resources (DDR)","address1":"5801 Beacon Street","address2":"","address3":"","address4":"","address5":"","city":"Pittsburgh","state":"PA","zip":"15217","country":"United States","phone":"","tty":"","tollFree":"800-497-0944","fax":"412-422-1374","email":"devdelay@mindspring.com","url":"http://www.devdelay.org"},{"resourceID":885,"resourceName":"The Society for Developmental and Behavioral Pediatrics","address1":"6728 Old McLean Village Drive","address2":"","address3":"","address4":"","address5":"","city":"McLean","state":"VA","zip":"22101","country":"United States","phone":"703-556-9222","tty":"","tollFree":"","fax":"","email":"info@sdbp.org","url":"http://www.sdbp.org/index.cfm"}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/271980' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omim&cmd=Display&dopt=omim_pubmed_calculated&from_uid=271980' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Succinic semialdehyde dehydrogenase deficiency. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Succinic+semialdehyde+dehydrogenase+deficiency%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Succinic semialdehyde dehydrogenase deficiency. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition=succinicsemialdehydedehydrogenasedeficiency' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Succinic semialdehyde dehydrogenase deficiency. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":838,"resourceId":1553,"resourceName":"succinic semialdehyde dehydrogenase deficiency","descriptionText":"Pearl PL, Gibson KM, Cortez MA, et al. <a href='http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693236/?tool=pubmed ' target='_blank'>Succinic semialdehyde dehydrogenase deficiency: Lessons from mice and men</a>. <em>J. Inherit. Metab. Dis.</em> 2009 June; 32(3):343-52.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Selected Full-Text Journal Articles"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/1113/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=22' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=ssadh' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:271980' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":5159,"questionText":"What is succinic semialdehyde dehydrogenase deficiency?","answerText":"<strong>Succinic semialdehyde dehydrogenase (SSADH) deficiency</strong> is a disorder that can cause a variety of neurological and neuromuscular&nbsp;problems. The signs and symptoms can be extremely variable among affected individuals and may include mild to severe intellectual disability; developmental delay (especially involving speech); <a href=\"http://www.ninds.nih.gov/disorders/hypotonia/hypotonia.htm\" target=\"_blank\">hypotonia</a>;&nbsp;difficulty coordinating&nbsp;movements (ataxia); and/or seizures. Some affected individuals may also have decreased reflexes (hyporeflexia); <a href=\"http://www.aoa.org/x9763.xml\" target=\"_blank\">nystagmus</a>; hyperactivity; and/or behavioral problems.[4199][4200] SSADH deficiency is caused by&nbsp;<a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=\"_blank\">mutations</a> in the <a href=\"http://ghr.nlm.nih.gov/gene/ALDH5A1\" target=\"_blank\"><em>ALDH5A1</em></a> gene and is inherited in an&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner.[4200]&nbsp;Management is generally symptomatic and typically focuses on treating seizures and neurobehavioral issues.[4201]","dateModified":"2013-09-25T15:54:00"},"basicQuestions":[{"questionId":7063,"questionText":"What are the symptoms of succinic semialdehyde dehydrogenase deficiency?","answerText":"People with&nbsp;succinic semialdehyde dehydrogenase deficiency&nbsp;(SSADH) typically have developmental delay, especially involving speech development; intellectual disability; and decreased muscle tone (<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003298.htm\" target=_blank>hypotonia</a>) soon after birth. About half of those affected experience seizures, difficulty coordinating movements (<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003198.htm\" target=_blank>ataxia</a>), decreased reflexes, and behavioral problems. The most common behavioral problems associated with this condition are sleep disturbances, hyperactivity, difficulty maintaining attention, and anxiety. Less frequently, affected individuals may have increased aggression, hallucinations, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000929.htm\" target=_blank>obsessive-compulsive disorder</a> (OCD), and self-injurious behavior, including biting and head banging. People with this condition can also have problems controlling eye movements. Less common features of SSADH include uncontrollable movements of the limbs (<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003197.htm\" target=_blank>choreoathetosis</a>), involuntary tensing of the muscles (<a href=\"http://www.nlm.nih.gov/medlineplus/dystonia.html\" target=_blank>dystonia</a>), muscle twitches (<a href=\"http://www.ninds.nih.gov/disorders/myoclonus/detail_myoclonus.htm\" target=_blank>myoclonus</a>), and a progressive worsening of ataxia.[4200]","dateModified":"2013-09-25T15:59:00","resourceClassificationName":"Symptoms","references":[{"referenceId":4200,"authors":"","articleTitle":"Succinic semialdehyde dehydrogenase deficiency","bookWebsiteJournalTitle":"Genetics Home Reference","date":"June 2008","url":"http://ghr.nlm.nih.gov/condition/succinic-semialdehyde-dehydrogenase-deficiency","dateAccessed":"2013-09-25T00:00:00"}]},{"questionId":7064,"questionText":"What causes succinic semialdehyde dehydrogenase deficiency?","answerText":"Succinic semialdehyde dehydrogenase deficiency (SSADH) is caused by mutations in the <span class=geneSymbol><em><a href=\"http://ghr.nlm.nih.gov/gene/ALDH5A1\" target=_blank>ALDH5A1</a></em></span> gene. This gene provides instructions for producing the succinic semialdehyde dehydrogenase enzyme which is involved in the breakdown of a chemical that transmits signals in the brain (neurotransmitter) called gamma-amino butyric acid (GABA). The primary role of GABA is to prevent the brain from being overloaded with too many signals. A shortage (deficiency) of succinic semialdehyde dehydrogenase leads to an increase in the amount of GABA and a related molecule called gamma-hydroxybutyrate (GHB) in the body, particularly the brain and spinal cord (central nervous system). It is unclear how an increase in GABA and GHB causes developmental delay, seizures, and other signs and symptoms of succinic semialdehyde dehydrogenase deficiency.[4200]","dateModified":"2013-09-25T16:01:00","resourceClassificationName":"Cause","references":[{"referenceId":4200,"authors":"","articleTitle":"Succinic semialdehyde dehydrogenase deficiency","bookWebsiteJournalTitle":"Genetics Home Reference","date":"June 2008","url":"http://ghr.nlm.nih.gov/condition/succinic-semialdehyde-dehydrogenase-deficiency","dateAccessed":"2013-09-25T00:00:00"}]},{"questionId":7065,"questionText":"How is succinic semialdehyde dehydrogenase deficiency inherited?","answerText":"Succinic semialdehyde dehydrogenase deficiency (SSADH) is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=_blank>autosomal recessive</a> pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.[4200]","dateModified":"2013-09-25T16:02:00","resourceClassificationName":"Inheritance","references":[{"referenceId":4200,"authors":"","articleTitle":"Succinic semialdehyde dehydrogenase deficiency","bookWebsiteJournalTitle":"Genetics Home Reference","date":"June 2008","url":"http://ghr.nlm.nih.gov/condition/succinic-semialdehyde-dehydrogenase-deficiency","dateAccessed":"2013-09-25T00:00:00"}]},{"questionId":5160,"questionText":"How is succinic semialdehyde dehydrogenase deficiency diagnosed?","answerText":"The diagnosis of succinic semialdehyde dehydrogenase (SSADH)&nbsp;deficiency is&nbsp;based upon a thorough clinical exam, the identification of features consistent with the condition, and a variety of specialized tests.[4199]&nbsp;SSADH deficiency may first be suspected in late infancy or early childhood in individuals who have <a href=\"http://www.ninds.nih.gov/disorders/encephalopathy/encephalopathy.htm\" target=_blank>encephalopathy</a>,&nbsp;a state in which brain function or structure is altered. The encephalopathy may be&nbsp;characterized by cognitive impairment; language deficit; poor muscle tone (hypotonia);&nbsp;seizures;&nbsp;decreased reflexes (hyporeflexia); and/or difficulty coordinating movements (ataxia). The diagnosis&nbsp;may be further suspected if urine organic acid analysis (a test that provides information about the substances the body discards through the urine) shows the presence of 4-hydroxybutyric acid.&nbsp;The diagnosis&nbsp;can be confirmed by an enzyme test showing deficiency of SSADH, or by genetic testing. <a href=\"http://ghr.nlm.nih.gov/gene/ALDH5A1\" target=_blank><em>ALDH5A1</em></a> is the only gene currently known to be associated with SSADH deficiency, and genetic testing&nbsp;can detect&nbsp;<a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=_blank>mutations</a> in&nbsp;about 97% of affected individuals.[4201]","dateModified":"2013-09-25T15:54:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":4199,"authors":"","articleTitle":"Succinic Semialdehyde Dehydrogenase Deficiency","bookWebsiteJournalTitle":"NORD","date":"2003","url":"http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/1113/viewAbstract","dateAccessed":"2013-09-25T00:00:00"},{"referenceId":4201,"authors":"Pearl PL, Dorsey AM, Barrios ES, Gibson KM","articleTitle":"Succinic Semialdehyde Dehydrogenase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"September 19, 2013","url":"http://www.ncbi.nlm.nih.gov/books/NBK1195/","dateAccessed":"2013-09-25T00:00:00"}]},{"questionId":7066,"questionText":"How might succinic semialdehyde dehydrogenase deficiency be treated?","answerText":"Treatment of&nbsp;succinic semialdehyde dehydrogenase deficiency (SSADH) is generally symptomatic and typically focuses on the treatment of seizures and neurobehavioral disturbances. Antiepileptic drugs (AEDs) that have proven to be effective in treating the seizures associated with this condition include <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682237.html\" target=_blank>carbamazepine</a> and <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a695007.html\" target=_blank>lamotrigine</a> (LTG). Medications such as <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682188.html\" target=_blank>methylphenidate</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682119.html\" target=_blank>thioridazine</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a694015.html\" target=_blank>risperidal</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a689006.html\" target=_blank>fluoxetine</a>, and <a href=\"http://www.getsmartaboutdrugs.com/drugs/benzodiazepines.html\" target=_blank>benzodiazepines</a> appear to be effective at treating anxiety, aggressiveness, inattention, and hallucinations. Additional treatments may include physical and occupational therapy, sensory integration, and/or speech therapy.[4201]","dateModified":"2013-09-25T16:04:00","resourceClassificationName":"Treatment","references":[{"referenceId":4201,"authors":"Pearl PL, Dorsey AM, Barrios ES, Gibson KM","articleTitle":"Succinic Semialdehyde Dehydrogenase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"September 19, 2013","url":"http://www.ncbi.nlm.nih.gov/books/NBK1195/","dateAccessed":"2013-09-25T00:00:00"}]},{"questionId":5162,"questionText":"What is the prognosis for individuals with succinic semialdehyde dehydrogenase deficiency?","answerText":"There has been very limited extended follow-up of this condition from childhood into adulthood, so little is known about the long-term prognosis&nbsp;for individuals with the condition.&nbsp;Because the nature and severity of signs and symptoms are so variable among affected individuals, the prognosis and quality of life likely depend on the&nbsp;specific features each affected individual has.<br><br>In the limited information available about SSADH deficiency in older individuals, it&nbsp;has been reported that the main neurobehavioral features present in adolescents and adults with the condition include attention deficit, hyperactivity, anxiety, obsession-compulsion, aggressive behavior, hallucinatory episodes, and autistic features.[4204] One article discussing how SSADH deficiency affected a single individual over 20 years reported that hyperactivity in adolescence evolved into moderate psychopathology in adulthood, which consisted of depression and obsession-compulsion. The authors of this study report that features in this individual are similar to those seen in others.&nbsp;They also stated that the individual did not have any further neurological deterioration over the 20-year period.[4204] However, this information about a single affected individual may not apply to other individuals with the condition.","dateModified":"2013-09-25T15:56:00","resourceClassificationName":"Prognosis","references":[{"referenceId":4204,"authors":"Crutchfield SR, Haas RH, Nyhan WL, Gibson KM.","articleTitle":"Succinic semialdehyde dehydrogenase deficiency: phenotype evolution in an adolescent patient at 20-year follow-up","bookWebsiteJournalTitle":"Developmental medicine and child neurology","date":"November 2008","volume":"50(11)","pages":"880-881","url":"http://www.ncbi.nlm.nih.gov/pubmed?term=18811705","dateAccessed":"2013-09-25T00:00:00"}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":32068,"abbreviatedInquiry":"How soon after birth can this be diagnosed? When is it known how severely an individual is affected? Is it possible to live a normal life?","caseQuestions":[{"questionId":5160,"questionText":"How is succinic semialdehyde dehydrogenase deficiency diagnosed?","answerText":"The diagnosis of succinic semialdehyde dehydrogenase (SSADH)&nbsp;deficiency is&nbsp;based upon a thorough clinical exam, the identification of features consistent with the condition, and a variety of specialized tests.[4199]&nbsp;SSADH deficiency may first be suspected in late infancy or early childhood in individuals who have <a href=\"http://www.ninds.nih.gov/disorders/encephalopathy/encephalopathy.htm\" target=_blank>encephalopathy</a>,&nbsp;a state in which brain function or structure is altered. The encephalopathy may be&nbsp;characterized by cognitive impairment; language deficit; poor muscle tone (hypotonia);&nbsp;seizures;&nbsp;decreased reflexes (hyporeflexia); and/or difficulty coordinating movements (ataxia). The diagnosis&nbsp;may be further suspected if urine organic acid analysis (a test that provides information about the substances the body discards through the urine) shows the presence of 4-hydroxybutyric acid.&nbsp;The diagnosis&nbsp;can be confirmed by an enzyme test showing deficiency of SSADH, or by genetic testing. <a href=\"http://ghr.nlm.nih.gov/gene/ALDH5A1\" target=_blank><em>ALDH5A1</em></a> is the only gene currently known to be associated with SSADH deficiency, and genetic testing&nbsp;can detect&nbsp;<a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=_blank>mutations</a> in&nbsp;about 97% of affected individuals.[4201]","dateModified":"2013-09-25T15:54:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":4199,"authors":"","articleTitle":"Succinic Semialdehyde Dehydrogenase Deficiency","bookWebsiteJournalTitle":"NORD","date":"2003","url":"http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/1113/viewAbstract","dateAccessed":"2013-09-25T00:00:00"},{"referenceId":4201,"authors":"Pearl PL, Dorsey AM, Barrios ES, Gibson KM","articleTitle":"Succinic Semialdehyde Dehydrogenase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"September 19, 2013","url":"http://www.ncbi.nlm.nih.gov/books/NBK1195/","dateAccessed":"2013-09-25T00:00:00"}]},{"questionId":5163,"questionText":"How early can succinic semialdehyde dehydrogenase deficiency be diagnosed?","answerText":"There is a wide variety in the range, severity and presentation of the symptoms of SSADH deficiency, so the time of diagnosis varies among affected individuals. Furthermore, some of the symptoms can be somewhat \"nonspecific\", potentially leading to difficulties with diagnosis.[4199] Studies have shown that the symptoms are first reported at a average age of 11 months (with a range of&nbsp;0-44 months), and the average&nbsp;age at diagnosis is approximately 6.6 years of age.[4201] Although symptoms are usually noticed during infancy or childhood, the disorder sometimes has not been diagnosed until adulthood.[4199]<br><br>In some cases, a diagnosis of SSADH deficiency may be considered before a child is born, especially if an unborn child is known to be at a high risk for being affected with the condition (i.e. if there is a family history of the condition or both parents are known carriers). Specialized tests during the pregnancy such as <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003921.htm\" target=_blank>amniocentesis</a> or&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003406.htm\" target=_blank>chorionic villus sampling</a> (CVS)&nbsp;may detect increased amounts of 4-hydroxybutyric acid in the amniotic fluid or deficient SSADH enzyme activity&nbsp;in cells of the fetus or placenta.[4199]","dateModified":"2011-08-30T15:03:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":4199,"authors":"","articleTitle":"Succinic Semialdehyde Dehydrogenase Deficiency","bookWebsiteJournalTitle":"NORD","date":"2003","url":"http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/1113/viewAbstract","dateAccessed":"2013-09-25T00:00:00"},{"referenceId":4201,"authors":"Pearl PL, Dorsey AM, Barrios ES, Gibson KM","articleTitle":"Succinic Semialdehyde Dehydrogenase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"September 19, 2013","url":"http://www.ncbi.nlm.nih.gov/books/NBK1195/","dateAccessed":"2013-09-25T00:00:00"}]},{"questionId":5161,"questionText":"When might it become apparent how severely affected an individual is?","answerText":"Unfortunately, there is no way to predict how severely affected an individual might be. Unrelated affected individuals show a very wide range in nature and severity of signs and symptoms. There may be more consistency within families, but this is not always the case. Furthermore, there appears to be no consistent relationship between the level of the SSADH&nbsp;enzyme present (or the mutations present) and the signs and symptoms that an individual manifests. The degree of severity generally depends on the specific signs and symptoms that develop in each affected individual and&nbsp;generally becomes apparent as the child ages.[4203]<br>","dateModified":"2011-09-01T10:24:00","references":[{"referenceId":4203,"authors":"Neil Gordon","articleTitle":"Succinic semialdehyde dehydrogenase deficiency (SSADH) (4-hydroxybutyric aciduria, ?-hydroxybutyric aciduria) ","bookWebsiteJournalTitle":"European Journal of Paediatric Neurology","date":"September 2004","volume":"8(5)","pages":"261-265"}]},{"questionId":5162,"questionText":"What is the prognosis for individuals with succinic semialdehyde dehydrogenase deficiency?","answerText":"There has been very limited extended follow-up of this condition from childhood into adulthood, so little is known about the long-term prognosis&nbsp;for individuals with the condition.&nbsp;Because the nature and severity of signs and symptoms are so variable among affected individuals, the prognosis and quality of life likely depend on the&nbsp;specific features each affected individual has.<br><br>In the limited information available about SSADH deficiency in older individuals, it&nbsp;has been reported that the main neurobehavioral features present in adolescents and adults with the condition include attention deficit, hyperactivity, anxiety, obsession-compulsion, aggressive behavior, hallucinatory episodes, and autistic features.[4204] One article discussing how SSADH deficiency affected a single individual over 20 years reported that hyperactivity in adolescence evolved into moderate psychopathology in adulthood, which consisted of depression and obsession-compulsion. The authors of this study report that features in this individual are similar to those seen in others.&nbsp;They also stated that the individual did not have any further neurological deterioration over the 20-year period.[4204] However, this information about a single affected individual may not apply to other individuals with the condition.","dateModified":"2013-09-25T15:56:00","resourceClassificationName":"Prognosis","references":[{"referenceId":4204,"authors":"Crutchfield SR, Haas RH, Nyhan WL, Gibson KM.","articleTitle":"Succinic semialdehyde dehydrogenase deficiency: phenotype evolution in an adolescent patient at 20-year follow-up","bookWebsiteJournalTitle":"Developmental medicine and child neurology","date":"November 2008","volume":"50(11)","pages":"880-881","url":"http://www.ncbi.nlm.nih.gov/pubmed?term=18811705","dateAccessed":"2013-09-25T00:00:00"}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":13037,"phenoTypeName":"Abnormality of metabolism/homeostasis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8720,"phenoTypeName":"Ataxia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8723,"phenoTypeName":"Global developmental delay","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8715,"phenoTypeName":"Intellectual disability","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8716,"phenoTypeName":"Muscular hypotonia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":6005,"phenoTypeName":"Behavioral abnormality","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13458,"phenoTypeName":"Bilateral tonic-clonic seizure","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13747,"phenoTypeName":"Generalized myoclonic seizure","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13751,"phenoTypeName":"Status epilepticus","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8731,"phenoTypeName":"Cerebellar atrophy","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":15655,"phenoTypeName":"Childhood onset","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13860,"phenoTypeName":"Delayed CNS myelination","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":14142,"phenoTypeName":"Delayed speech and language development","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":9384,"phenoTypeName":"Generalized hypotonia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":8725,"phenoTypeName":"Hyporeflexia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":6245,"phenoTypeName":"Infantile onset","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":12793,"phenoTypeName":"Juvenile onset","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":8729,"phenoTypeName":"Motor delay","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":8719,"phenoTypeName":"Seizure","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":15654,"phenoTypeName":"Young adult onset","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":5607,"phenoTypeName":"Abnormality of eye movement","percentRanges":"-"},{"phenoTypeId":6013,"phenoTypeName":"Aggressive behavior","percentRanges":"-"},{"phenoTypeId":14132,"phenoTypeName":"Anxiety","percentRanges":"-"},{"phenoTypeId":6012,"phenoTypeName":"Autism","percentRanges":"-"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":1772,"phenoTypeName":"Decreased succinic semialdehyde dehydrogenase level","percentRanges":"-"},{"phenoTypeId":11431,"phenoTypeName":"EEG abnormality","percentRanges":"-"},{"phenoTypeId":1771,"phenoTypeName":"Elevated circulating gamma-aminobutyric acid concentration","percentRanges":"-"},{"phenoTypeId":1774,"phenoTypeName":"Elevated CSF 4-hydroxybutyric acid concentration","percentRanges":"-"},{"phenoTypeId":1773,"phenoTypeName":"Elevated CSF gamma-aminobutyric acid concentration","percentRanges":"-"},{"phenoTypeId":1770,"phenoTypeName":"Elevated urinary 4-hydroxybutyric acid","percentRanges":"-"},{"phenoTypeId":13746,"phenoTypeName":"Generalized non-motor (absence) seizure","percentRanges":"-"},{"phenoTypeId":14131,"phenoTypeName":"Hallucinations","percentRanges":"-"},{"phenoTypeId":14144,"phenoTypeName":"Hyperactivity","percentRanges":"-"},{"phenoTypeId":14284,"phenoTypeName":"Hyperkinetic movements","percentRanges":"-"},{"phenoTypeId":2138,"phenoTypeName":"Increased level of gamma-aminobutyric acid in urine","percentRanges":"-"},{"phenoTypeId":3822,"phenoTypeName":"Psychomotor retardation","percentRanges":"-"},{"phenoTypeId":6006,"phenoTypeName":"Psychosis","percentRanges":"-"},{"phenoTypeId":11801,"phenoTypeName":"Self-injurious behavior","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Succinic_semialdehyde_dehydrogenase_deficiency"}